SNCA and Parkinson disease: Detection of misfolded alpha-synuclein is now feasible, but it lacks quantitation,8 which is needed to predict the risk of poor outcomes in and track the progression of Parkinson’s disease.5 This barrier to the development of disease-modifying therapies is likely due in part to disease heterogeneity and multiple underlying mechanisms.